Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Viral-Vector Delivered anti-Angiogenic Therapies to the Eye

Version 1 : Received: 22 December 2020 / Approved: 23 December 2020 / Online: 23 December 2020 (17:45:44 CET)

A peer-reviewed article of this Preprint also exists.

Koponen, S.; Kokki, E.; Kinnunen, K.; Ylä-Herttuala, S. Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye. Pharmaceutics 2021, 13, 219. Koponen, S.; Kokki, E.; Kinnunen, K.; Ylä-Herttuala, S. Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye. Pharmaceutics 2021, 13, 219.

Journal reference: Pharmaceutics 2021, 13, 219
DOI: 10.3390/pharmaceutics13020219

Abstract

Pathological vessel growth harms vision and may finally lead to vision loss. Anti-angiogenic gene therapy with viral vectors for ocular neovascularization has shown great promise in pre-clinical studies. Most of the studies has conducted with different adeno-associate serotype vectors. In addition, Adeno and lentivirus vectors have been used. Therapy has targeted to block vascular endothelial growth factors or other pro-angiogenic factors. Clinical trials of intraocular gene therapy for neovascularization have shown the treatment to be safe without severe adverse events or systemic effects. Nevertheless, clinical studies have not proceeded phase 2 trials further.

Subject Areas

Gene therapy; ocular neovascularization; viral vectors; preclinical; clinical trials; anti-angiogenesis; AAV

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.